G/TBT/N/EU/842  
14 October 2021  
(21-7763) Page: 1/2 
Committee on Technical Barriers to Trade  Original:  English  
 
  
NOTIFICATION  
The following notification is being circulated in accordance with Article 10.6  
 
1. Notifying Member:  EUROPEAN UNION   
If applicable, name of local government involved (Article 3.2 and 7.2):   
2. Agency responsible:  European Commission  
Name and address (including telephone and fax numbers , email and website 
addresses, if available) of agency or authority designated to handle comments 
regarding the notification shall be indicated if different from above:   
European Comm ission,  
EU-TBT Enquiry Point,  
Fax: +(32) 2 299 80 43,  
E-mail: grow-eu-tbt@ec.europa.eu  
Website: http://ec.europa.eu/growth/tools -databases/tb t/en/  
3. Notified under Article 2.9.2 [X], 2.10.1 [   ], 5.6.2 [   ], 5.7.1 [   ], other :  
4. Products covered (HS or CCCN  where applicable, otherwise national tariff 
heading. ICS numbers may be provided in addition, where applicable):  Chemical 
substances classified as drug precursors.; Pharmaceutics (ICS 11.120), Products of the 
chemical industry (ICS 71.100)  
5. Title, numb er of pages and language(s) of the notified document:  Draft 
Commission Delegated Regulation amending Regulation (EC) No 273/2004 of the 
European Parliament and of the Council and Council Regulation (EC) No 111/2005 as 
regards the inclusion of certain drug precursors in the list of scheduled substances (6 
page(s), in English; 3 page(s), in English)  
6. Description of content:  This draft Commission Regulation adds ethyl alpha -
phenylacetoacetate (EAPA) and methyl 3 -oxo-2-(3,4-methylenedioxyphenyl)butanoate 
(MAMDPA) to Category 1 of the list of scheduled substances in Regulation (EC) No 
111/2005 laying down rules for the monitoring of trade between the Community and third 
countries in drug precursors.  
Operators engaged in import, export or intermediary activitie s involving scheduled 
substances listed in Category 1 of the Annex have the obligation to hold a licence. Special 
labelling requirements apply for any packaging containing these substances according to 
Article 5 of the Regulation.  
7. Objective and rationale, including the nature of urgent problems where 
applicable:  EAPA is a pre -precursor in the production of amphetamine and 
methamphetamine. MAMDPA is a pre -precursor of 3,4 -methylenedioxymethamphetamine 
(MDMA), commonly known as 'ecstasy'. The use o f these drugs is causing serious social 
and public health problems in some regions of the Union. As there is no known legal use 
for EAPA and MAMDPA except for research purposes, their inclusion in Category 1 of drug 
precursors in Regulation (EC) No 111/200 5 is appropriate to address those risks, and any G/TBT/N/EU/842  
 
- 2 - 
 
  additional restriction on trade is justified by the objectives pursued. ; Protection of human 
health or safety  
8. Relevant documents:  Article 12 of the UN Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 19.12.1988;  
Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade 
between the Union and third countries in drug precursors.  
http://eur -lex.europa.eu/legal -
content/EN/TXT/?qid=1426599802066&uri=CELEX:32005R0111  
9. Proposed date of adoption:  Spring 2022  
Proposed date of entry into force:  The provisions will enter into force and apply 20 
days after their publication in the Official Journal of the EU. Given that no legal use for 
EAPA except research is known, no transitional period is envisaged.  
10. Final date for comments:  60 days from no tification  
11. Texts available from:  National enquiry point [ ] or address, telephone and fax 
numbers and email and website addresses, if available , of other body:   
European Commission,  
EU-TBT Enquiry Point,  
Fax: + (32) 2 299 80 43,  
E-mail: grow-eu-tbt@ec.europa.eu  
 
The text is available on the EU -TBT Website : http://ec.europa.eu/growth/tools -
databases/tbt/en/  
 
https://members.wto.org/crnattachments/2021/TBT/EEC/21_6559_00_e.pdf  
https://members.wto.org/crnattachmen ts/2021/TBT/EEC/21_6559_01_e.pdf